Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Hidradenitis suppurativa is a disease involving skin folds, causing swelling of the skin and
surrounding tissues, pain, and foul-smelling discharges. Effective treatment options are
lacking. Recently, clinical trials conducted in our lab found Brodalumab was an effective
drug for this disease. Weekly dosing achieved superior therapeutic outcomes compared to a
dosing given once in every other week. Brodalumab was safe in both regimens, but blood and
tissue studies to better understand this response are still needed. By performing this small
pilot study and collecting blood and tissue samples from participants treated with Brodalumab
once weekly we would like to better characterize the molecular response to this treatment,
identify blood and tissue markers reflecting disease severity, and better understand disease
mechanisms.